Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

WALGREEN PHARMACY SALES INCREASE 17% THROUGH SIX MONTHS ENDING FEB. 29

Executive Summary

Walgreen Co. pharmacy sales increased 17% for the six months ended Feb. 29, the company reported March 30. Prescription sales in stores that had been open for at least a year were up 14.1% for the first half of the company's fiscal year. For the quarter, pharmacy sales increased 17.4%, Walgreen said. Total sales for the six months increased 11.5%, to $3.75 bil. For the quarter, sales were up 11.9%, topping $2 bil., Walgreen said. Earnings growth surpassed sales increases. For the six months, earnings rose 13% to $112.6 mil. For the quarter, earnings were up 14.3% to $77.1 mil. The earnings results were helped by a one- time charge taken in the year-ago period of $4.1 mil. for closing Walgreen's Memphis distribution center, the company noted. Excluding the charge, earnings grew 10.2% for the six months and 10.1% for the quarter. "Profitability was helped by good cost control measures, which lowered both headquarters and store salary expenses as a percentage of sales," Walgreen said. "Advertising and store occupancy expenses as a percent of sales were also lower for the quarter. These were partially offset by higher insurance expenses." Walgreen opened 47 new stores during the six months, the company noted. As of March 31, the company operated 1,692 stores in 29 states and Puerto Rico compared to 1,599 last year. The company expects to open a total of 110 new stores this year, and 125 next year. Two generic firms reported impressive 1991 sales growth. Royce Labs announced a 32.4% increase in revenues for the year ended Dec. 31, 1991, as revenues climbed to $2 mil. Halsey Drug sales increased 42% in 1991. Net sales reached $37.5 mil. for the year. Halsey Drug's fourth quarter sales grew even more strongly than its annual sales, up 46% to $11.4 mil. Net income for the year was $1.7 mil., up 72%. For the quarter, net income was up 39% to $451,000.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Latest Headlines
See All
UsernamePublicRestriction

Register

PS020675

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel